Searchable abstracts of presentations at key conferences in endocrinology

ea0090ep744 | Pituitary and Neuroendocrinology | ECE2023

Growth hormone treatment tends to promote hepatic VLDL1-triglyceride export in humans

Baumgartner Clemens , Metz Matthaeus , Schnait Franziska , Tosin Anna , Beghini Marianna , Fellinger Paul , Beiglboeck Hannes , Pfleger Lorenz , Vila Greisa , Luger Anton , Kautzky-Willer Alexandra , Stangl Herbert , Krssak Martin , Furnsinn Clemens , Scherer Thomas , Krebs Michael , Wolf Peter

Introduction: Non-alcoholic fatty liver disease (NAFLD) is a systemic, metabolic condition associated with increased morbidity and mortality. Defined by an increase in hepatic lipid content (HCL), NAFLD develops in consequence of lipid oversupply and/or a diminished disposal of hepatic lipids. The latter may include an impaired export of triglycerides (TG) via the secretion of very-low density lipoprotein1 (VLDL1) particles, an important mechanism of the liver to protect itsel...

ea0099oc12.3 | Oral Communications 12: Diabetes, Obesity, Metabolism and Nutrition | Part II | ECE2024

Growth hormone promotes in-vivo hepatic triglyceride export in humans

Baumgartner Clemens , Metz Matthaeus , Pfleger Lorenz , Tosin Anna , Beghini Marianna , Beiglboeck Hannes , Fellinger Paul , Schnait Franziska , Vila Greisa , Luger Anton , Kautzky-Willer Alexandra , Freudenthaler Angelika , Baumgartner-Parzer Sabina , Stangl Herbert , Krssak Martin , Scherer Thomas , Krebs Michael , Wolf Peter

Overview: Non-alcoholic fatty liver disease (NAFLD) is defined as a chronic increase in intrahepatic lipids (IHL). A surplus of IHL can be compensated through increased lipid export via very-low density lipoprotein (VLDL) particles. Growth hormone (GH) is known to reduce visceral and ectopic fat. However, the main pathways responsible for the in-vivo decrease of IHL under the influence of GH are yet to be determined.Methods: We assessed hepatic lipid met...

ea0099rc5.7 | Rapid Communications 5: Pituitary and Neuroendocrinology | Part I | ECE2024

Changes of hepatic metabolism and lipidomic profile with biochemical improvement of acromegaly

Fellinger Paul , Pfleger Lorenz , Beiglboeck Hannes , Baumgartner Clemens , Marella Nara , Micko Alexander , Wolfsberger Stefan , Vila Greisa , Lmger Anton , Kautzky-Willer Alexandra , Krssak Martin , Scherer Thomas , Wolf Peter , Krebs Michael , Winhofer Yvonne

Overview: Despite marked insulin resistance, patients with active acromegaly have low hepatocellular lipid content (IHL) and an unfavourable hepatic lipid composition (UI). As previously shown, inadequate mitochondrial activity in the liver might counteract lipid accumulation in the liver. The purpose of this study was to understand changes in hepatic metabolism, and lipidomic profile with therapy of acromegaly.Methods: We prospectively included thirteen...